A quantitative measure that evaluates the proportion of data points in the treatment phase that exceed the most extreme value in the baseline phase. The strength of this analysis is that it is simple and conservative. The two phase series must be largely non-overlapped in order to exceed at least the 70% non-overlap threshold to be considered noticeable.
